Mr Bourla also announced that Pfizer is in discussions with the Indian government seeking an “expedited approval pathway” for its COVID-19 vaccine.
Pfizer Chairman and CEO Albert Bourla on Monday said the company is sending its medicines worth USD 70 million (over ₹ 510 crore), from its distribution centres in the US, Europe and Asia, which have been identified as part of India’s COVID-19 treatment protocol.
In a mail sent to Pfizer India employees that he has shared on his linked.in post, he said: “We are deeply concerned by the critical COVID-19 situation in India, and our hearts go out to you, your loved ones and all the people of India.”
“We are committed to being a partner in India’s fight against this disease and are quickly working to mobilize the largest humanitarian relief effort in our company’s history,” Mr Bourla said.
He added that currently Pfizer colleagues at distribution centres in the US, Europe and Asia are hard at work rushing shipments of Pfizer medicines that the Government of India has identified as part of its COVID-19 treatment protocol.
“We are donating these medicines to help make sure that every COVID-19 patient in every public hospital across the country can have access to the Pfizer medicines they need free of charge,” Mr Bourla said.
These medicines, valued at more than USD 70 million, will be made available immediately, and “we will work closely with the government and our NGO partners to get them to where they are needed most,” the Pfizer CEO said.
At the same time, Mr Bourla also announced that Pfizer is in discussions with the Indian government seeking an “expedited approval pathway” for its COVID-19 vaccine.
“Unfortunately, our vaccine is not registered in India although our application was submitted months ago,” he said.
“We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country.”